# US 2004/0018975 A1 · Use of GLP-1 analogs and derivatives administered peripherally in regulation of obesity

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2004/0018975 A1
- Document ID: US20040018975A1
- Status: Published application
- Kind: A1
- Application number: 10/429,522
- Filed: 2003-05-05
- Published: 2004-01-29
- Earliest claimed: 1996-11-05
- Assignees: Eli Lilly and Company
- Inventors: Richard DiMarchi; Suad Efendic
- Web page: https://patentgrep.com/patent/US20040018975A1

## CPC

- C07K 14/605: Glucagons
- A61K 38/26: Glucagons
- A61P 3/04: Anorexiants; Antiobesity agents
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

This invention relates the use of glucagon-like peptides such as GLP-1, a GLP-1 analog, or a GLP-1 derivative in methods and compositions for reducing body weight.

## Claims

### Claim 1

A method of reducing body weight by administering to a subject a composition comprising a glucagon-like peptide-1, or an analog or derivative thereof.

### Claim 2

A method of reducing body weight, comprising, administering to a subject a composition comprising a compound selected from the group consisting of GLP-1, GLP-1 analogs, GLP-1 derivatives, agonists of the GLP-1 receptor, agonists of the GLP-1 signal transduction cascade, compounds that stimulate synthesis of endogenous GLP-1, compounds that stimulate release of endogenous GLP-1, and pharmaceutically-acceptable salts thereof, in a dose sufficient to cause reduction in body weight.

### Claim 3 (depends on 2)

The method of claim 2, wherein the compound is selected from the group consisting of GLP-1, GLP-1 analogs, GLP-1 derivatives, and pharmaceutically-acceptable salts thereof.

### Claim 4 (depends on 2)

The method of claim 2, wherein the compound administered is GLP-1 (7-36) amide, or a pharmaceutically-acceptable salt thereof.

### Claim 5 (depends on 2)

The method of claim 2, wherein the compound administered is Val8-GLP-1(7-37)OH, or a pharmaceutically-acceptable salt thereof.

### Claim 6 (depends on 2)

The method of claim 2, wherein the administering of the composition is by a peripheral parenteral route.

### Claim 7 (depends on 6)

The method of claim 6, wherein the administering of the composition is intravenously.

### Claim 8 (depends on 6)

The method of claim 6, wherein the administering of the composition is subcutaneously.

### Claim 9 (depends on 3)

The method of claim 3, wherein the administering of the composition is continuous.

### Claim 10 (depends on 9)

The method of claim 9, wherein the administering of the composition is at a rate of between 0.25 and 6 pmol/kg/min.

### Claim 11 (depends on 9)

The method of claim 9, wherein the administering of the composition is at a rate of between 0.6 and 2.4 pmol/kg/min.

### Claim 12 (depends on 5)

The method of claim 5, wherein the intravenous administration is intermittent.

### Claim 13

A method of reducing body weight, comprising, administering to a subject a composition comprising a compound selected from the group consisting of agonists of the GLP-1 receptor, agonists of the GLP-1 signal transduction cascade, compounds that stimulate synthesis of endogenous GLP-1, compounds that stimulate release of endogenous GLP-1, and pharmaceutically-acceptable salts thereof, in a dose sufficient to cause reduction in body weight.

### Claim 14

A composition used for the reduction of body weight, said composition comprising a glucagon-like peptide-1, or an analog, derivative, or active fragment thereof.
